MaaT Pharma
MaaT Pharma
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-04-03 | NCT07001618 | |
| Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) | Transplant Complication | Recruiting | Phase 2 | 2024-12-27 | NCT05762211 | |
| MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD | Active, not recruiting | Phase 3 | 2024-10-17 | NCT04769895 |